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insured urban population in China. Methods: A pooled cross-sectional analy-
sis was performed using China Health Insurance Research Association Database 
of year 2010, 2011 and 2012. Hospitalizations with T2D were identified using 
ICD-10 codes. Adult patients without any cancer or ketoacidosis were included. 
Descriptive statistics were used to analyze hospitalization costs and medication 
usage in T2D patients by age group cut at 60. Results: A total of 11,157 T2D hos-
pitalization records from 13 cities were analyzed, with 56.77% are elderly patients, 
and 32% of total patients have at least one comorbidity. The mean length of stay 
(LOS) per admission was 16 days in elderly patients, and 14 days in patients under 
60. The average direct cost per hospitalization and reimbursement ratio in elderly 
patients were ¥9,036.74 (±7675.74) and 77.34%, compared to ¥8084.34 (±5304.76) 
and 72.11% in patients under 60, respectively. On average, LOS was found 1 day 
longer, and hospitalization costs were found ¥1120 higher in T2D patients with 
comorbidities compared to those without. The average number of medications 
used per admission was 13 and 11 in patients ≧ 60 and under 60, respectively. 
In T2D elderly patients, majority (68.92%) used combination of oral antidiabetic 
drugs (OAD) and insulin. Acarbose and metformin were the most 2 frequently 
used OAD in all treatment choices. For non-antidiabetic medications, the most 
two frequently used drugs were aspirin and mecobalamine. ConClusions: Direct 
medical cost is considerable in elderly T2D patients under hospitalization, espe-
cially in those with comorbidities. The study also showed a complex medication 
usage pattern in elderly population.
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objeCtives: Chronic Kidney Disease (CKD) is a common comorbidity of Type 
2 Diabetes (T2D). This study is to explore the direct cost and medication usage 
pattern in T2D with CKD inpatients among insured urban population in Beijing 
and Tianjin, China. Methods: A pooled cross-sectional analysis was performed 
using hospitalization records in Beijing and Tianjin from China Health Insurance 
Research Association Database of year 2010, 2011 and 2012. Hospitalizations with 
T2D and CKD were identified using ICD-10 codes. Adult patients without any 
cancer or ketoacidosis were included. Descriptive statistics were used to analyze 
hospitalization costs and medication usage. Results: A total of 810 T2D with 
CKD hospitalizations were identified, accounting for 20.1% of the total T2D hospi-
talizations. The mean age (±SD) showed on the records were 62.42 (±11.78) years, 
with 16.15±8.92 days length of stay. The direct cost per admission was 10,155.68 
(±7,614.79), with 77.5% reimbursed by basic medical insurance. Medication cost 
accounted for 47.55% of the total cost, among which 29.57% were antidiabet-
ics. Averaged 15+ drugs were prescribed per admission. For T2D treatment 
choices, 13.33% patients used oral antidiabetic drugs (OAD) alone, and 66.75% 
used OAD and insulin combination. Acarbose and metformin were the two most 
frequently used OADs in all treatment choices. For non-T2D related medication 
treatment in T2D with CKD patients, aspirin and nifedipine were the two most 
frequently used drugs. Drugs on renin-angiotensin system (RAS) were the 5thfre-
quently used non-antidiabetics. ConClusions: Managing T2D among patients 
with CKD could be challenging given the renal impairment. This study showed 
that the direct cost in T2D patients with CKD per hospitalization was consid-
erable and their medicine usage pattern was complex in Beijing and Tianjin in 
China. More attention should be paid to the rational use of medication in such 
population.
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objeCtives: To quantify the association between weight change, diabetes-
related healthcare costs, and HbA1c among patients with type 2 diabetes (T2D); 
analyses were also conducted in sub-group of obese patients with no prior car-
diovascular disease. Methods: This retrospective, observational cohort study 
used U.S. insurance claims linked to laboratory and electronic medical records. 
Study included patients with T2D who were age≥ 18 years and added/switched to 
a non-metformin antidiabetes medication after metformin monotherapy between 
Jan-1-2007-Jun-30-2012 (add/switch date= index). Primary predictor was percent-
age weight change (PWC) between weight measurement at index and follow-up 
measurement 6 months thereafter ranging from negative (loss) to positive (gain). 
Outcomes, measured in 12-month period beginning at follow-up weight meas-
urement, included HbA1c< 7 and diabetes-related healthcare costs. Multivariable 
models quantified the association between PWC (linear effect) and study out-
comes. Results: Primary analysis included 1,520 patients (mean age 55 years; 
47% female); sub-group analysis included 780 patients (mean age 53 years; 51% 
female). Mean (SD) index weight and PWC were 224.6 (52.8) lbs and +0.2% (4.7%) in 
primary analysis; 241.3 (47.3) lbs and -0.2% (4.6%) in sub-group analysis. Negative 
PWC values were significantly associated with higher adjusted probabilities of 
achieving HbA1c< 7 (primary analysis: 58.8 % for PWC of -5% vs. 46.7% for PWC 
of +5%, P< 0.001; sub-group 63.2% for PWC -5% vs. 41.7% for PWC .5%, P< 0.001). 
Increasing PWC was significantly associated with increasing diabetes-specific 
pharmacy costs (P< 0.001) in primary analysis sample and with increasing all-
cause pharmacy costs (P= 0.018), diabetes-specific total costs (P= 0.039), diabetes-
specific medical costs (P= 0.002), and diabetes-specific pharmacy costs (P< 0.001) 
in sub-group sample. PWC was not significantly associated with all-cause total 
was used to estimate the cost of treating T2DM patients to two composite endpoints 
in a UK setting, using 208 week data from a previously published double-blind 
randomised clinical trial of dapagliflozin (DAPA) vs glipizide (GLIP) (NCT00660907). 
Calculation of costs included drug acquisition costs, cost for adverse events, micro- 
and macrovascular complications, and BMI related costs The cost of treating one 
patient to the composite endpoints using DAPA+MET versus GLIP+MET over 208 
weeks was calculated as total cost per treatment arm divided by number of patients 
that reached the composite endpoint in each arm. Results: The number needed 
to treat was 4 for DAPA+MET and 35 for GLIP+MET and overall cost of treating 
one patient over 208 weeks to composite endpoint (1) was £12,042 for DAPA+MET 
and £50,040 for GLIP+MET. The corresponding figures for composite endpoint (2) 
was 4 for DAPA+MET and 47 for GLIP+MET with corresponding costs of £12,666 
and £59,366. ConClusions: The cost of treating one patient to the composite 
endpoints was approximately 4.1-4.7 times higher with GLIP+MET compared to 
DAPA+MET. These results demonstrate that when multiple treatment goals, 
including weight loss and reduction of hypoglycaemic events are targeted, the cost 
of treating patients with DAPA+MET is lower compared to GLIP+MET.
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objeCtives: To correlate spending on diabetes drug prescriptions in English gen-
eral practices with occurrence of risks associated with type 2 diabetes. Methods: 
Data from the HSCIC showing number of prescriptions, by drug, issued in English 
general practices in 2014 and the associated net ingredient cost (NIC) were ana-
lysed using a proprietary in-house software. The total number of patients per CCG 
with diagnosed diabetes, stroke and ischemia, peripheral atrial disease, hyper-
tension, heart failure, coronary heart disease and atrial fibrillation between April 
2013 and March 2014 were identified through the HSCIC’s QOF data. The median 
age in a CCG was identified using ONS 2012 data. Spearman’s correlations and 
partial correlations were performed using SPSS v22.0. ‘Spend’ was defined as 
total NIC. Results: As expected, spending on prescriptions for diabetes drugs 
correlated almost perfectly with the number of diabetes patients (r= 0.97***). All 
the included risks associated with diabetes, bar age, correlated significantly with 
spending on diabetes prescriptions. The highest correlation was with the number 
of patients with obesity (r= 0.92***). The most expensive type of diabetes drugs were 
insulins. The correlations between spend on insulin prescriptions and number 
of patients with each individual diabetes risk was always higher than the cor-
relations between spend on prescriptions for all diabetes drugs and number of 
patients with each individual associated risk. The same was true when correlating 
the total number of prescriptions with occurrence of diabetes associated risks. 
Interestingly, both of these trends remained true when controlling for number of 
patients diagnosed with diabetes using partial correlations. ConClusions: As 
the occurrence of risks associated with diabetes increase, the spend on diabetes 
prescriptions is likely to increase. This is not only because more prescriptions 
are issued but also because the likelihood of insulins, the most expensive type of 
diabetes drugs, being prescribed increases.
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objeCtives: To examine the longitudinal effects and key costs of medication non 
adherence in patients with diabetes mellitus. Methods: The prospective study 
was conducted over a period of six months in a South Indian Village. Adherence to 
treatment has been assessed during a personal interview with each patient by using 
questionnaire. Medication adherence was assessed by using Morisky medication 
adherence scale (MMAS). Results: A total of 658 patients were diagnosed with 
Type 2 diabetes mellitus among them 87% (n= 572) of the patients were prescribed 
with oral hypoglycemic agents for more than a year were selected as study popula-
tion. The statistical significant association with socio demographic and adherence 
rate to antidiabetic therapy indicated that higher prevalence of adherence among 
uneducated (41.22%) elderly (32.82%) women (42.26%) unemployed (29.95%). The 
most common causes for nonadherence to taking medications were lack of knowl-
edge (35.25%) unaffordability () experience of untoward reactions (15.62%). Feeling 
better (26.5%). The adherence levels were 35 %( poor adherence), 27% (medium), 
and 38% (high). Among the poor adherence, 24 patients were hospitalized due to 
diabetic complications like, diabetic foot ulcer (n= 13), diabetic ketoacidosis (07), 
diabetic nephropathy (01), diabetic retinopathy (03). 5 patients were admitted due 
to diabetes induced renal failure. ConClusions: In conclusion, our study revealed 
that poor adherence leads hospitalization and increases the economic burden of 
diabetic patient. By conducting diabetes awareness camps and continued medica-
tion education programme through diabetic centers in village setup can significantly 
reduces the non adherences.
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objeCtives: Elderly population is growing and so is the prevalence of diabetes 
among them. The present study was to explore direct medical cost and medication 
usage pattern in hospitalized elderly patients with type 2 diabetes (T2D) among 
